Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
Initial Safety Data for IMP761: Immutep Limited reports favorable initial safety results from the Phase I study of IMP761, a LAG-3 agonist designed to treat autoimmune diseases, with no treatment-related adverse events observed in healthy participants so far.
Future Developments: Additional safety data and pharmacokinetic/pharmacodynamic assessments are expected in the first half of CY2025, as the trial aims to evaluate the drug's effectiveness in restoring immune system balance by silencing dysregulated T cells.
Trade with 70% Backtested Accuracy
Analyst Views on IMMP
No data
About IMMP
About the author
Immutep's TACTI-004 Trial Reaches 50% Enrollment Milestone
- Enrollment Progress: Immutep has enrolled 378 patients in the TACTI-004 trial, achieving 50% of its target enrollment, indicating strong momentum in developing innovative cancer immunotherapies, which is expected to enhance its market competitiveness.
- Clinical Trial Scale: The trial aims to recruit approximately 756 patients across over 140 clinical sites in 27 countries, demonstrating Immutep's extensive collaboration and resource integration capabilities globally, aimed at improving treatment efficacy and expanding the patient base.
- Efficacy Analysis Timeline: Immutep anticipates completing the efficacy analysis in Q1 2026 and patient enrollment by Q3 2026, with this timeline laying the groundwork for subsequent clinical data release and market promotion, thereby boosting investor confidence.
- Therapeutic Potential: The combination of Efti with KEYTRUDA and chemotherapy is poised to establish a new standard of care in non-small cell lung cancer treatment, particularly in enhancing patient survival rates and improving clinical outcomes, which could significantly alter the existing treatment landscape.
Immutep's First LAG-3 Antibody Trial Shows Positive Phase I Results
- Clinical Trial Progress: Immutep's IMP761 has completed the 2.5 and 7 mg/kg dosing levels in a Phase I trial with healthy participants, demonstrating positive safety and efficacy data without serious adverse reactions, indicating its potential in treating autoimmune diseases.
- Immunosuppressive Effects: The drug exhibited dose-dependent immunosuppressive effects, achieving significant and long-lasting inhibition of T-cell-mediated intradermal reactions to a strong foreign antigen on days 2, 9, and 23, potentially offering new treatment avenues for conditions like rheumatoid arthritis.
- Market Opportunity: As a therapeutic target for autoimmune diseases, LAG-3 positions IMP761 to address large markets, including Type 1 diabetes and multiple sclerosis, which could translate into multi-billion dollar opportunities for the company.
- Future Outlook: Immutep plans to continue the trial as scheduled, with additional updates expected in the first half of 2026, further enhancing market interest and investor confidence in this promising program.
ASX Penny Stocks Highlight: DUG Technology Featured Among Three Key Selections
Market Overview: Australian shares are facing challenges due to global tech sector declines, prompting investors to consider penny stocks, which may offer surprising value and stability despite their smaller size.
DUG Technology Ltd: This technology company, with a market cap of A$281.66 million, has shown improvement in financial health, reducing losses significantly over the past five years, and has potential for future growth despite current profitability challenges.
Immutep Limited: A biotechnology firm focused on immunotherapies, Immutep has a market cap of A$552.65 million and is well-positioned financially, with a strong cash position supporting ongoing clinical trials, despite being pre-revenue.
Wagners Holding Company: With a market cap of A$719.01 million, Wagners has demonstrated robust financial health and significant earnings growth, supported by its inclusion in the S&P/ASX Emerging Companies Index, although it faces challenges with long-term liabilities.
Immutep Secures Exclusive Eftilagimod Alfa Licensing Deal with Dr. Reddy's for $20M Upfront Payment
- Strategic Collaboration: Immutep has entered into an exclusive licensing agreement with Dr. Reddy's for Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China, which is expected to significantly enhance Efti's market penetration.
- Substantial Financial Returns: Under the agreement, Immutep will receive an upfront payment of $20 million and is eligible for potential milestone payments of up to $349.5 million, ensuring future revenue growth for the company.
- Global Market Control: Immutep retains global manufacturing rights for Efti in North America, Europe, and Japan, ensuring continued control in key markets while expanding influence in other regions through collaboration with Dr. Reddy's.
- Innovative Therapy Prospects: Efti, as a novel immunotherapy, is currently undergoing a Phase III clinical trial for non-small cell lung cancer, and if successful, it will set a new standard in cancer treatment, further enhancing Immutep's competitiveness in the biopharmaceutical industry.
Highlights of ASX Penny Stocks: Immutep and Two Other Notable Selections
Market Overview: The Australian market is facing volatility, with ASX 200 futures indicating a significant drop due to economic uncertainties, while penny stocks remain attractive to investors for their growth potential.
Highlighted Penny Stocks: Notable penny stocks on the ASX include Alfabs Australia, Dusk Group, and IVE Group, which are recognized for their financial health and growth prospects amidst current market conditions.
Immutep Limited: This biotechnology company, focused on immunotherapies for cancer, has a market cap of A$404.78 million and is showing promising clinical trial results despite being pre-revenue.
Omni Bridgeway Limited: With a market cap of A$449.96 million, this company has transitioned to profitability, reporting significant revenue and strong liquidity, while Propel Funeral Partners Limited operates in the death care sector with stable financial performance.
EFTISARC-NEO Phase II Trial Achieves Primary Endpoint for Neoadjuvant Efti in Soft Tissue Sarcoma, Findings Revealed at ESMO Congress 2025
Positive Trial Results: The EFTISARC-NEO Phase II trial demonstrated that the combination of eftilagimod alfa (efti) with radiotherapy and KEYTRUDA® achieved a median of 51.5% tumor hyalinization/fibrosis in patients with soft tissue sarcoma, significantly exceeding the target of 35% (p<0.001).
Significance of Findings: This level of tumor hyalinization/fibrosis is over three times greater than historical results from standard radiotherapy alone, suggesting potential improvements in overall and recurrence-free survival for patients with soft tissue sarcoma.
Immutep's TACTI-004 Trial Reaches 50% Enrollment Milestone
- Enrollment Progress: Immutep has enrolled 378 patients in the TACTI-004 trial, achieving 50% of its target enrollment, indicating strong momentum in developing innovative cancer immunotherapies, which is expected to enhance its market competitiveness.
- Clinical Trial Scale: The trial aims to recruit approximately 756 patients across over 140 clinical sites in 27 countries, demonstrating Immutep's extensive collaboration and resource integration capabilities globally, aimed at improving treatment efficacy and expanding the patient base.
- Efficacy Analysis Timeline: Immutep anticipates completing the efficacy analysis in Q1 2026 and patient enrollment by Q3 2026, with this timeline laying the groundwork for subsequent clinical data release and market promotion, thereby boosting investor confidence.
- Therapeutic Potential: The combination of Efti with KEYTRUDA and chemotherapy is poised to establish a new standard of care in non-small cell lung cancer treatment, particularly in enhancing patient survival rates and improving clinical outcomes, which could significantly alter the existing treatment landscape.
Immutep's First LAG-3 Antibody Trial Shows Positive Phase I Results
- Clinical Trial Progress: Immutep's IMP761 has completed the 2.5 and 7 mg/kg dosing levels in a Phase I trial with healthy participants, demonstrating positive safety and efficacy data without serious adverse reactions, indicating its potential in treating autoimmune diseases.
- Immunosuppressive Effects: The drug exhibited dose-dependent immunosuppressive effects, achieving significant and long-lasting inhibition of T-cell-mediated intradermal reactions to a strong foreign antigen on days 2, 9, and 23, potentially offering new treatment avenues for conditions like rheumatoid arthritis.
- Market Opportunity: As a therapeutic target for autoimmune diseases, LAG-3 positions IMP761 to address large markets, including Type 1 diabetes and multiple sclerosis, which could translate into multi-billion dollar opportunities for the company.
- Future Outlook: Immutep plans to continue the trial as scheduled, with additional updates expected in the first half of 2026, further enhancing market interest and investor confidence in this promising program.
ASX Penny Stocks Highlight: DUG Technology Featured Among Three Key Selections
Market Overview: Australian shares are facing challenges due to global tech sector declines, prompting investors to consider penny stocks, which may offer surprising value and stability despite their smaller size.
DUG Technology Ltd: This technology company, with a market cap of A$281.66 million, has shown improvement in financial health, reducing losses significantly over the past five years, and has potential for future growth despite current profitability challenges.
Immutep Limited: A biotechnology firm focused on immunotherapies, Immutep has a market cap of A$552.65 million and is well-positioned financially, with a strong cash position supporting ongoing clinical trials, despite being pre-revenue.
Wagners Holding Company: With a market cap of A$719.01 million, Wagners has demonstrated robust financial health and significant earnings growth, supported by its inclusion in the S&P/ASX Emerging Companies Index, although it faces challenges with long-term liabilities.
Immutep Secures Exclusive Eftilagimod Alfa Licensing Deal with Dr. Reddy's for $20M Upfront Payment
- Strategic Collaboration: Immutep has entered into an exclusive licensing agreement with Dr. Reddy's for Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China, which is expected to significantly enhance Efti's market penetration.
- Substantial Financial Returns: Under the agreement, Immutep will receive an upfront payment of $20 million and is eligible for potential milestone payments of up to $349.5 million, ensuring future revenue growth for the company.
- Global Market Control: Immutep retains global manufacturing rights for Efti in North America, Europe, and Japan, ensuring continued control in key markets while expanding influence in other regions through collaboration with Dr. Reddy's.
- Innovative Therapy Prospects: Efti, as a novel immunotherapy, is currently undergoing a Phase III clinical trial for non-small cell lung cancer, and if successful, it will set a new standard in cancer treatment, further enhancing Immutep's competitiveness in the biopharmaceutical industry.
Highlights of ASX Penny Stocks: Immutep and Two Other Notable Selections
Market Overview: The Australian market is facing volatility, with ASX 200 futures indicating a significant drop due to economic uncertainties, while penny stocks remain attractive to investors for their growth potential.
Highlighted Penny Stocks: Notable penny stocks on the ASX include Alfabs Australia, Dusk Group, and IVE Group, which are recognized for their financial health and growth prospects amidst current market conditions.
Immutep Limited: This biotechnology company, focused on immunotherapies for cancer, has a market cap of A$404.78 million and is showing promising clinical trial results despite being pre-revenue.
Omni Bridgeway Limited: With a market cap of A$449.96 million, this company has transitioned to profitability, reporting significant revenue and strong liquidity, while Propel Funeral Partners Limited operates in the death care sector with stable financial performance.
EFTISARC-NEO Phase II Trial Achieves Primary Endpoint for Neoadjuvant Efti in Soft Tissue Sarcoma, Findings Revealed at ESMO Congress 2025
Positive Trial Results: The EFTISARC-NEO Phase II trial demonstrated that the combination of eftilagimod alfa (efti) with radiotherapy and KEYTRUDA® achieved a median of 51.5% tumor hyalinization/fibrosis in patients with soft tissue sarcoma, significantly exceeding the target of 35% (p<0.001).
Significance of Findings: This level of tumor hyalinization/fibrosis is over three times greater than historical results from standard radiotherapy alone, suggesting potential improvements in overall and recurrence-free survival for patients with soft tissue sarcoma.
